Lack of interaction between verapamil and cimetidine

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacology

Background:

• Drug interactions can significantly alter therapeutic outcomes.
• Cimetidine is known to inhibit certain cytochrome P450 enzymes, potentially affecting the metabolism of other drugs.
• Verapamil and lidocaine are commonly used cardiovascular and antiarrhythmic agents, respectively.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic interactions between cimetidine and verapamil.
• To assess the effect of cimetidine on lidocaine clearance in healthy volunteers.

Main Methods:

• Healthy subjects received intravenous and oral verapamil before and during cimetidine administration.
• Pharmacokinetic parameters (t1/2, volume of distribution, clearance, AUC, bioavailability) were measured.
• Lidocaine clearance and half-life were evaluated during cimetidine therapy.
• Verapamil's pharmacodynamic effects on ECG, blood pressure, and heart rate were monitored.

Main Results:

• Cimetidine did not significantly change verapamil's half-life, volume of distribution, total clearance, plasma AUC, or absolute bioavailability.
• Lidocaine clearance was significantly reduced by cimetidine (P < 0.05).
• A trend towards a longer lidocaine half-life was observed during cimetidine therapy.
• Verapamil's pharmacodynamic effects, including changes in blood pressure and heart rate, were not altered by cimetidine.

Conclusions:

• Cimetidine does not appear to significantly interact with verapamil pharmacokinetics or pharmacodynamics.
• Cimetidine can inhibit lidocaine clearance, suggesting a potential for drug interactions.
• Clinicians should be aware of the potential for cimetidine to alter the metabolism of certain drugs, like lidocaine.